ABSTRACT

Background: Wound healing proceeds through hemostasis, inflammation, proliferation, and remodeling. Chronic wounds, including diabetic foot, venous, and pressure ulcers, stall in a persistent inflammatory state driven by impaired perfusion, oxidative stress, infection, and repeated trauma. Standard care centers on debridement, moist wound management, infection control, offloading or compression, and correction of underlying disease.

Evidence: In animal models, FIR accelerated wound closure and collagen deposition without raising skin temperature (Toyokawa et al. 2003), sped diabetic wound healing in a dose-dependent manner with increased angiogenic signaling (Chen et al. 2021), and outperformed a heat-matched control in diabetic wounds while shifting macrophages toward a reparative phenotype (Jian et al. 2026). Human data are limited to perfusion studies (Kraaij et al. 2024) and one controlled diabetic foot ulcer trial of a broad-spectrum infrared lamp (Hakim et al. 2016).

Positioning: FIR is a promising investigational adjunct with consistent preclinical evidence and a plausible, partly non-thermal mechanism. It is not a substitute for professional wound care. Heat must not be applied to insensate or ischemic tissue, and no human trial has established FIR for chronic wound healing.

1. Introduction

Acute wounds in healthy individuals usually heal predictably. Chronic wounds do not. Diabetic foot ulcers, venous leg ulcers, and pressure injuries affect millions of people, carry high rates of infection and amputation, and consume a large share of healthcare resources. Their common features include poor tissue perfusion, persistent inflammation dominated by pro-inflammatory (M1) macrophages, excess oxidative stress, impaired angiogenesis, and reduced fibroblast activity.

Interest in far infrared (FIR) for wound healing stems from two observations: FIR increases skin microcirculation (Yu et al. 2006; Kraaij et al. 2024), and several animal studies report effects that persist when temperature is controlled, suggesting a wavelength-specific biological action (Toyokawa et al. 2003; Jian et al. 2026). This review evaluates that evidence and defines the boundaries for its use.

2. Biology of Healing and Its Failure

• Hemostasis (minutes to hours): Clot formation and release of growth factors.
• Inflammation (days): Neutrophils and macrophages clear debris and pathogens; a timely switch from M1 to reparative M2 macrophages is required for progression.
• Proliferation (days to weeks): Fibroblasts deposit collagen, endothelial cells form new vessels (angiogenesis), and keratinocytes re-epithelialize the surface.
• Remodeling (weeks to months): Collagen matures and reorganizes, increasing tensile strength.
• Chronic wound failure: Ischemia, hyperglycemia, oxidative stress, infection, and pressure or edema trap the wound in inflammation.

3. Far Infrared Biophysics and Delivery Formats

Far infrared radiation (approximately 4–14 µm) is absorbed predominantly in the superficial skin. Animal wound studies have used both very low-intensity emitters positioned at a distance (0.13 mW/cm² at 20 cm) (Chen et al. 2021) and heated emitters (Jian et al. 2026). Passive emitters, including mineral topicals and carbon or graphene textiles, provide low-intensity, non-heating exposure. Whole-body FIR, such as the Relax Sauna (PTC semiconductor emitters, 95–99% emissivity, 9.4 µm peak, head-out design), produces systemic warming and sweating and is not appropriate as a wound treatment while wounds are open.

4. Clinical Evidence

4.1 Acute wounds (animal)

In rats with full-thickness skin wounds, FIR accelerated wound closure by day 7 compared with both normal and temperature-matched controls, increased collagen fiber area from 26.5% to 56.8%, and increased fibroblast infiltration and TGF-β1 expression (Toyokawa et al. 2003). Skin temperature and blood flow did not change, supporting a non-thermal mechanism.

4.2 Diabetic wounds (animal)

In streptozotocin-diabetic rats with large full-thickness wounds, a low-intensity FIR emitter (5–12 µm, peak 8.2 µm) applied for 20 or 40 minutes three times weekly significantly accelerated healing compared with untreated diabetic controls (p<0.001), with 40-minute sessions healing faster than 20-minute sessions (5.8 vs 7.1 weeks) (Chen et al. 2021). FIR increased eNOS, VEGF, EGF, and Ki-67 and reduced inflammatory (CD45) and oxidative (8-OHdG) markers, with a dose-response pattern.

In a second diabetic rat model, a graphene FIR film and a metal heating film were both held at 41 °C, isolating the contribution of FIR emission from heat (Jian et al. 2026). At day 14, closure reached 83.9% with graphene FIR, 74.2% with the heat-matched control, and 66.8% in untreated diabetic wounds. Graphene FIR roughly halved wound TNF-α and IL-6, shifted macrophages from M1 toward M2, and increased Nrf2 and antioxidant gene expression.

4.3 Human evidence

In 50 patients with grade 1–2 diabetic foot ulcers, daily 20-minute infrared lamp treatment added to routine dressings for four weeks produced partial or full recovery in all treated patients versus 32% of controls, with worsening in 0% versus 20% (Hakim et al. 2016). The device was a tungsten infrared lamp with an unreported wavelength, likely weighted toward near infrared, and follow-up was short. In healthy adults, an FIR-emitting patch increased local skin perfusion and microcirculation (Kraaij et al. 2024).

4.4 Evidence Summary

5. Mechanistic Pathways

6. Explicit Positioning — What We Do Not Claim

• FIR is not a treatment for chronic wounds in humans. No randomized trial of a defined FIR device has shown improved healing of human chronic wounds.
• FIR does not replace debridement, infection management, offloading, compression, glycemic control, or vascular assessment.
• Heat must not be applied to insensate (neuropathic) or ischemic tissue, where it can cause burns or increase metabolic demand beyond blood supply.
• FIR does not treat wound infection and should never delay care for signs of infection.
• Animal findings, including graphene film results, should not be presented as human outcomes, and broad infrared lamp results should not be presented as FIR outcomes.

7. Open Question — What a Definitive Trial Would Need

• Population: Adults with non-ischemic diabetic foot ulcers (adequate perfusion confirmed by ankle-brachial or toe pressures) receiving standardized care including offloading.
• Arms: Standard care plus a defined, non-heating FIR emitter versus standard care plus sham emitter, with blinded wound assessment.
• Primary endpoint: Proportion of ulcers completely healed at 12 weeks.
• Secondary endpoints: Time to healing, wound area reduction, transcutaneous oxygen, infection, amputation, recurrence at 12 months, and adverse skin events.
• Dose characterization: Wavelength, irradiance, distance, skin temperature, and session duration recorded.

8. Clinical Guidance

9. Conclusion

Three independent animal studies show that FIR accelerates wound closure, angiogenesis, and resolution of inflammation, including in diabetic wounds, with effects that persist when heat is controlled. These findings align with FIR-specific NRF2 and nitric oxide signaling confirmed in humans. Human wound evidence remains limited to perfusion data and a single trial of a broad-spectrum infrared lamp. FIR is best positioned as a promising investigational adjunct for wound care, used only alongside professional management and never as heat on insensate or ischemic tissue, while well-designed human trials are undertaken.